GlassScriptPhysician profile
Amanda Ruth Collier
NPI 1477850915
$4,454.19
in general payments reported to CMS, 2019-2025
35 companies · $913 in 2025
The $913 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $783 · 2022: $1,066 · 2023: $818 · 2024: $875 · 2025: $913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,605.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,706.89 | 2021-2025 | |
| Janssen Biotech, INC. | $390.50 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $342.96 | 2022-2025 | Xifaxan |
| Genzyme Corporation | $257.86 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $186.20 | 2021-2025 | Entyvio, Eohilia |
| Phathom Pharmaceuticals, INC. | $169.47 | 2024-2025 | Voquezna |
| Pfizer INC. | $122.53 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $106.39 | 2021-2022 | |
| Lilly USA, LLC | $79.17 | 2021-2025 | Omvoh |
| Celltrion USA INC. | $75.49 | 2024-2025 | Vegzelma |
| Ardelyx, INC. | $73.86 | 2023-2025 | Ibsrela |
| Biohaven Pharmaceuticals, INC. | $73.24 | 2021 | |
| Glaxosmithkline, LLC. | $70.87 | 2021-2023 | Shingrix |
| Regeneron Healthcare Solutions, INC. | $68.47 | 2022-2025 | Dupixent |
| Novo Nordisk INC | $68.17 | 2021-2025 | Wegovy |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $65.91 | 2022-2024 | Zeposia |
| Esperion Therapeutics, INC. | $61.98 | 2021 | |
| Amarin Pharma, INC. | $60.72 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $55.97 | 2024-2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $46.41 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.12 | 2021 | |
| Nestle Healthcare Nutrition INC. | $44.88 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.01 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $36.11 | 2021 | |
| Aimmune Therapeutics, INC. | $34.14 | 2024-2025 | Zenpep |
| Redhill Biopharma INC. | $23.94 | 2021 | |
| Madrigal Pharmaceuticals | $20.24 | 2025 | Rezdiffra |
| Echosens North America, INC. | $17.42 | 2025 | Fibroscan |
| Optinose US, INC. | $16.84 | 2021 | |
| Braintree Laboratories, INC. | $16.42 | 2023 | Suflave |
| Intercept Pharmaceuticals, INC. | $16.32 | 2023 | Ocaliva |
| Astellas Pharma US INC | $14.62 | 2022 | |
| Fresenius Kabi USA, LLC | $14.30 | 2023 | Idacio |
| Amgen INC. | $13.80 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Collier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.